Payment overview · 2025
General Payments
$1,037.07
60 reported records · 15 companies
Healthcare provider profile · identity verified
William A Hayes, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CAPE CORAL, FL · NPI 1710937537
Verified facts
What the public records show
CMS Open Payments records show William A Hayes, D.O. received $1,037.07 in general payments during 2025 across 60 reported records.
Amgen Inc. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $211.67 | 20.4% | 18 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $171.73 | 16.6% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $149.08 | 14.4% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.49 | 8.2% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $74.42 | 7.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.10 | 7.0% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $57.02 | 5.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $42.46 | 4.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.19 | 4.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.16 | 3.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.64 | 2.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.56 | 1.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.79 | 1.7% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $17.24 | 1.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.52 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,037.07 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $134.34 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.78 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $106.38 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $106.38 | 11 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $105.29 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $74.42 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $73.10 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $71.16 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $57.02 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $44.73 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $42.46 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $42.46 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.76 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.76 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.39 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.16 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.45 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.64 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.30 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $11.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 77 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
171 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 546 | 180 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 545 | 170 |
| Pantoprazole Sodium | Pantoprazole Sodium | 418 | 143 |
| Losartan Potassium | Losartan Potassium | 343 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 316 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 252 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 243 | 76 |
| Lisinopril | Lisinopril | 242 | 78 |
| Alprazolam | Alprazolam | 237 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 234 | 74 |
| Omeprazole | Omeprazole | 219 | 69 |
| Valsartan | Valsartan | 183 | 63 |
| Eliquis | Apixaban | 171 | 47 |
| Metformin Hcl | Metformin Hcl | 170 | 62 |
| Tramadol Hcl | Tramadol Hcl | 164 | 40 |
| Simvastatin | Simvastatin | 162 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 44 |
| Gabapentin | Gabapentin | 130 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 36 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 116 | 33 |
| Allopurinol | Allopurinol | 106 | 34 |
| Meloxicam | Meloxicam | 98 | 42 |
| Sertraline Hcl | Sertraline Hcl | 95 | 34 |
| Montelukast Sodium | Montelukast Sodium | 93 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 23 |
| Trazodone Hcl | Trazodone Hcl | 89 | 35 |
| Furosemide | Furosemide | 83 | 31 |
| Lorazepam | Lorazepam | 83 | 20 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 82 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 27 |
| Jardiance | Empagliflozin | 77 | 31 |
| Prednisone | Prednisone | 77 | 46 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 77 | 64 |
| Xarelto | Rivaroxaban | 77 | 26 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 73 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 25 |
| Azithromycin | Azithromycin | 72 | 67 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 24 |
| Ozempic | Semaglutide | 68 | 22 |
| Clonazepam | Clonazepam | 66 | 19 |
| Carvedilol | Carvedilol | 64 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 25 |
| Methylprednisolone | Methylprednisolone | 63 | 51 |
| Albuterol Sulfate | Albuterol Sulfate | 62 | 44 |
| Ezetimibe | Ezetimibe | 61 | 22 |
| Finasteride | Finasteride | 60 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 23 |
| Donepezil Hcl | Donepezil Hcl | 56 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 15 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Spironolactone | Spironolactone | 55 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 53 | 24 |
| Temazepam | Temazepam | 53 | 19 |
| Bupropion Xl | Bupropion Hcl | 51 | 14 |
| Glimepiride | Glimepiride | 51 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 51 | 15 |
| Memantine Hcl | Memantine Hcl | 49 | suppressed |
| Synthroid | Levothyroxine Sodium | 49 | 13 |
| Atenolol | Atenolol | 47 | 16 |
| Celecoxib | Celecoxib | 47 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 13 |
| Januvia | Sitagliptin Phosphate | 46 | 14 |
| Potassium Chloride | Potassium Chloride | 46 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 13 |
| Torsemide | Torsemide | 44 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 15 |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Lovastatin | Lovastatin | 39 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 16 |
| Venlafaxine Hcl | Venlafaxine Hcl | 37 | 12 |
| Diazepam | Diazepam | 36 | 16 |
| Fenofibrate | Fenofibrate | 36 | 12 |
| Cefdinir | Cefdinir | 34 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 12 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 26 |
| Fluconazole | Fluconazole | 30 | 17 |
| Pregabalin | Pregabalin | 30 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 14 |
| Famotidine | Famotidine | 28 | 11 |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 15 |
| Cephalexin | Cephalexin | 25 | 20 |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 22 | 20 |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 18 |
| Baclofen | Baclofen | 19 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 16 |
| Ramipril | Ramipril | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Itraconazole | Itraconazole | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,037.07 · 60 records | Amgen Inc. | ABRYSVO, AREXVY, CAPVAXIVE, COMIRNATY, EVENITY, Extended Holter, GARDASIL 9, GEMTESA, INSPIRE, JARDIANCE, Korlym, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VENASEAL, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error